N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Intravenous Lidocaine Infusion in Lumbar Fusion Surgery

Sponsor: Ankara City Hospital Bilkent • ClinicalTrials.gov ID: NCT07488832

Registry updated: 2026-09-25
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties. This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery. The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.

Interventions

  • Lidocaine (Drug)
    Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg/kg/h following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.
  • Normal Saline (Drug)
    An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.

Eligibility criteria

Inclusion Criteria: * Age ≥18 years * Scheduled for elective lumbar fusion surgery under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Ability to provide written informed consent Exclusion Criteria: * Refusal to participate in the study * ASA physical status ≥IV * Body mass index \>35 kg/m² * Known allergy or hypersensitivity to lidocaine or study medications * Severe cardiac, hepatic, or renal disease * Pregnancy * Neurological disorders affecting pain assessment * Chronic opioid use * Use of opioids or antiemetic drugs before surgery * Inability to cooperate with postoperative assessments

Conditions

Lumbar Fusion Surgery

Locations

  • Ankara Bilkent City Hospital — Ankara, Turkey (Türkiye)
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record